Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2004

01-03-2004 | Article

Impact of Drug-Resistant Mycobacterium tuberculosis on Treatment Outcome of Culture-Positive Cases of Tuberculosis in the Archangel Oblast, Russia, in 1999

Authors: O. S. Toungoussova, N. I. Nizovtseva, A. O. Mariandyshev, D. A. Caugant, P. Sandven, G. Bjune

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2004

Login to get access

Abstract

The objective of this study was to evaluate the outcome of treatment of culture-positive cases of tuberculosis registered in Archangel, Russia, in 1999, and to analyse the influence of Mycobacterium tuberculosis drug resistance on treatment outcome. The outcome of tuberculosis treatment was evaluated for 235 new and 61 previously treated culture-positive cases diagnosed in 1999. Of the 235 new cases, there were 150 (63.8%) cases of treatment completion, 20 (8.5%) cases of treatment failure, 29 (12.3%) cases of death during treatment, and 29 (12.3%) cases in which the patient failed to pick up medications for at least 2 consecutive months. The outcome in 7 (3%) cases was unknown, as the patients were transferred outside the oblast region. Among the 61 previously treated cases, the rate of treatment completion was low (26.2%), and rates of treatment failure (23%) and failure to pick up medications for at least 2 consecutive months (29.5%) were high. The relation between the susceptibility pattern of the infecting strain as determined by the Bactec method and tuberculosis treatment outcome was analysed for 76 patients. The majority (69%) of patients infected with drug-susceptible strains was cured. A large proportion (58.8%) of patients infected with Mycobacterium tuberculosis resistant to more than two drugs did not respond to treatment, i.e. the treatment failed or the patients died. The high rates of death (16.7%) and failure (66.7%) among patients infected with multidrug-resistant strains illustrate the negative impact of multidrug resistance on the outcome of tuberculosis treatment. Pan-resistance was significantly associated with treatment failure (P<0.001). The spread of resistant Mycobacterium tuberculosis has a serious negative impact on the outcome of tuberculosis treatment in Archangel, Russia.
Literature
1.
go back to reference Perelman MI (2000) Tuberculosis in Russia. Int J Tuberc Lung Dis 4:1097–1103PubMed Perelman MI (2000) Tuberculosis in Russia. Int J Tuberc Lung Dis 4:1097–1103PubMed
2.
go back to reference Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G (2002) Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in the Archangels oblast, Russia. Int J Tuberc Lung Dis 6:406–414PubMed Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G (2002) Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in the Archangels oblast, Russia. Int J Tuberc Lung Dis 6:406–414PubMed
3.
go back to reference WHO Geneva/IUATLD Paris (1998) Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2:72–89PubMed WHO Geneva/IUATLD Paris (1998) Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2:72–89PubMed
4.
go back to reference Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC (2000) Standard short-course chemotherapy for drug-resistant tuberculosis treatment outcomes in 6 countries. JAMA 283:2537–2545CrossRefPubMed Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC (2000) Standard short-course chemotherapy for drug-resistant tuberculosis treatment outcomes in 6 countries. JAMA 283:2537–2545CrossRefPubMed
5.
go back to reference Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA (2002) Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis 6:585–591PubMed Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA (2002) Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis 6:585–591PubMed
6.
go back to reference Sevim T, Atac G, Gungor G, Torun T, Aksoy E, Gemci I, Tahaoglu K (2002) Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis 6:320–325PubMed Sevim T, Atac G, Gungor G, Torun T, Aksoy E, Gemci I, Tahaoglu K (2002) Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis 6:320–325PubMed
7.
go back to reference Kim SJ, Bai GH, Hong YP (1997) Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1:302–308PubMed Kim SJ, Bai GH, Hong YP (1997) Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1:302–308PubMed
8.
go back to reference Flament-Saillour M, Robert J, Jarlier V, Grosset J (1999) Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 160:587–593PubMed Flament-Saillour M, Robert J, Jarlier V, Grosset J (1999) Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 160:587–593PubMed
9.
go back to reference The World Bank (1993) Investing in health: world development report 1993. Oxford University Press, New York The World Bank (1993) Investing in health: world development report 1993. Oxford University Press, New York
10.
go back to reference World Health Organization, Communicable Diseases Programme (2000) Global tuberculosis control. WHO, Geneva, p 275 World Health Organization, Communicable Diseases Programme (2000) Global tuberculosis control. WHO, Geneva, p 275
11.
go back to reference Blower SM, Daley CL (2002) Problems and solutions for the Stop TB partnership. Lancet Infect Dis 2:374–376CrossRefPubMed Blower SM, Daley CL (2002) Problems and solutions for the Stop TB partnership. Lancet Infect Dis 2:374–376CrossRefPubMed
12.
go back to reference World Health Organization (2003) Treatment of tuberculosis: guidelines for national programmes. WHO, Geneva, p 112 World Health Organization (2003) Treatment of tuberculosis: guidelines for national programmes. WHO, Geneva, p 112
13.
go back to reference Enarson DA, Rieder HL, Arnadottir T, Trebucq A (1996) Tuberculosis guide for low-income countries. International Union Against Tuberculosis and Lung Diseases, Paris, p 65 Enarson DA, Rieder HL, Arnadottir T, Trebucq A (1996) Tuberculosis guide for low-income countries. International Union Against Tuberculosis and Lung Diseases, Paris, p 65
14.
go back to reference Mariandyshev AO, Nizovtseva NI, Dityatev VI (2001) Treatment of patients with tuberculosis. Programme of short-course chemotherapy. Northern State Medical University, Arkhangelsk, Russia, p 26 Mariandyshev AO, Nizovtseva NI, Dityatev VI (2001) Treatment of patients with tuberculosis. Programme of short-course chemotherapy. Northern State Medical University, Arkhangelsk, Russia, p 26
15.
go back to reference Inderlied CB, Pfyffer GE (2003) Susceptibility test methods: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH (eds) Manual of clinical microbiology. American Society for Microbiology, Washington DC, pp 1149–1177 Inderlied CB, Pfyffer GE (2003) Susceptibility test methods: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH (eds) Manual of clinical microbiology. American Society for Microbiology, Washington DC, pp 1149–1177
16.
go back to reference Pfaller MA (1994) Application of new technology to the detection, identification, and antimicrobial susceptibility testing of mycobacteria. Am J Clin Pathol 101:329–337PubMed Pfaller MA (1994) Application of new technology to the detection, identification, and antimicrobial susceptibility testing of mycobacteria. Am J Clin Pathol 101:329–337PubMed
17.
go back to reference Siddiqi SH (1995) BACTEC 460 TB System. Product and procedure manual, revision. Becton Dickinson Microbiology Systems, Sparks, MD, USA Siddiqi SH (1995) BACTEC 460 TB System. Product and procedure manual, revision. Becton Dickinson Microbiology Systems, Sparks, MD, USA
18.
go back to reference Centers for Disease Control and Prevention (2001) Evaluation of a directly observed therapy short-course strategy for treating tuberculosis in Orel oblast, Russian Federation, 1999–2000. Morb Mortal Wkly Rep 50:204–206 Centers for Disease Control and Prevention (2001) Evaluation of a directly observed therapy short-course strategy for treating tuberculosis in Orel oblast, Russian Federation, 1999–2000. Morb Mortal Wkly Rep 50:204–206
19.
go back to reference Centers for Disease Control and Prevention (2001) Tuberculosis treatment interruptions in Ivanovo oblast, Russian Federation, 1999. Morb Mortal Wkly Rep 50:201–204 Centers for Disease Control and Prevention (2001) Tuberculosis treatment interruptions in Ivanovo oblast, Russian Federation, 1999. Morb Mortal Wkly Rep 50:201–204
20.
go back to reference Laszlo A, Rahman M, Espinal M, Raviglione M, and the WHO/IUATLD Network of Supranational Reference Laboratories (2002) Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994–1998. Int J Tuberc Lung Dis 6:748–756PubMed Laszlo A, Rahman M, Espinal M, Raviglione M, and the WHO/IUATLD Network of Supranational Reference Laboratories (2002) Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994–1998. Int J Tuberc Lung Dis 6:748–756PubMed
21.
go back to reference Mitchison DA (1998) How drug resistance emerges as a result of poor compliance during short-course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2:10–15PubMed Mitchison DA (1998) How drug resistance emerges as a result of poor compliance during short-course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2:10–15PubMed
22.
go back to reference Kruuner A, Pehme L, Ghebremichael S, Koivula T, Hoffner SE, Mikelsaar M (2002) Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis. Clin Infect Dis 35:146–155CrossRefPubMed Kruuner A, Pehme L, Ghebremichael S, Koivula T, Hoffner SE, Mikelsaar M (2002) Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis. Clin Infect Dis 35:146–155CrossRefPubMed
Metadata
Title
Impact of Drug-Resistant Mycobacterium tuberculosis on Treatment Outcome of Culture-Positive Cases of Tuberculosis in the Archangel Oblast, Russia, in 1999
Authors
O. S. Toungoussova
N. I. Nizovtseva
A. O. Mariandyshev
D. A. Caugant
P. Sandven
G. Bjune
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2004
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-1080-6

Other articles of this Issue 3/2004

European Journal of Clinical Microbiology & Infectious Diseases 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.